BASF Pharma Solutions has announced a price increase of up to 20% for its excipients and select active pharmaceutical ingredients (APIs), effective immediately. This decision comes in response to escalating energy and raw material costs that have been impacting the pharmaceutical supply chain.
The rising costs of energy and raw materials have been a persistent challenge for manufacturers in the pharmaceutical sector, significantly affecting production expenses. As companies like BASF adjust their pricing strategies, it highlights the broader trend of inflationary pressures that are reshaping the industry landscape.
This price hike may compel pharmaceutical companies to reassess their sourcing strategies and budget allocations, potentially leading to increased costs for end products. Stakeholders in regulatory, quality assurance, and supply chain management will need to navigate these changes carefully to maintain compliance and ensure product availability in a competitive market.
Start your 7-day trial and see what the database can do →
